Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy

Kam, Grace; Yiu, Richard; Loh, Yvonne; Ang, Ai Leen; Yueh, Ling Ling; Goh, Yeow Tee; Wong, Gee Chuan

doi:10.1007/s00520-014-2417-7

Cited by 6 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Incidence of positive microbiological cultures was lesser in the GCSF arm compared to the peg GCSF arm, though the difference was not signi cant. This nding again was different from that in the previous study [32].…”

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

Single dose of peg GCSF compared with daily GCSF in de novo acute myeloid leukemia patients on high dose cytarabine consolidation chemotherapy (HIDAC)

Ghosh

2024

Preprint

View full text Add to dashboard Cite

Background: Consolidation therapy with high dose cytarabine (HIDAC) for Acute Myeloid Leukemia (AML)is associated with significant neutropenia , resultant infections and associated morbidities. In this prospective study on de novo AML patients we attempted to compare efficacy of peg GCSF vs GCSF in ameliorating the duration and severity of neutropenia. Material and methods: Fifty eight cycles of HIDAC(1,3,5) from 20 patients were studied. Twenty four hours after the consolidation chemotherapy, patients were randomized to receive either once daily short-acting GCSF (5 µg/kg) or single dose of long acting peg GCSF(6mg/100 µg per kg). Results: The median duration of neutropenia and episodes of febrile neutropenia were 9.0 and 15 in the GCSF arm and 9.8 days and 17 in the peg GCSF arm, respectively (p >0.05).. Incidence of positive microbiological cultures and mean duration of hospital stay was similar in the two arms. Conclusion: The results of this study failed to show any difference in the incidence and duration of febrile neutropenia, incidence of infections and associated morbidities, with the use of GCSF compared to peg GCSF in patients of AML on HIDAC consolidation therapy.

show abstract

Section: Discussioncontrasting

confidence: 99%

“…The mean duration of neutropenia and that of hospital stay was similar to previously reported study, which however, reported a lesser duration of febrile neutropenia [32]. Incidence of positive microbiological cultures was lesser in the GCSF arm compared to the peg GCSF arm, though the difference was not signi cant.…”

Section: Discussionsupporting

confidence: 87%

Single dose of peg GCSF compared with daily GCSF in de novo acute myeloid leukemia patients on high dose cytarabine consolidation chemotherapy (HIDAC)

Ghosh

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The recommended dose of PEG rhG-CSF for chemotherapy-induced neutropenia was single-dose 100 μg/kg or a fixed dose of 6 mg per chemotherapeutic cycle. Previous studies indicated that the efficacy and safety of the dosage of PEG rhG-CSF in one chemotherapy cycle at 6 mg was well compared with 11 daily injections of rhG-CSF at 5 μg/kg/d in treating neutropenia (8)(9)(10)(11)(12). In addition, single dose of 100 μg/kg PEG rhG-CSF also displayed the similar protection function compared with daily rhG-CSF injection in patients receiving myelo-suppressive chemotherapy regimens (11,13,14).…”

Section: Introductionmentioning

confidence: 91%

A phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia

Qin¹,

Han²,

Wang³

et al. 2017

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

The pharmacokinetic and pharmacodynamic profiles of PEG rhG-CSF used in cancer patients were similar to those reported, as well as the safety. Double half dose administration model showed better efficacy result than a single dose model in terms of grade 3 neutropenia and above. The single dose of 60 μg/kg, 100 μg/kg and double half dose of 30 μg/kg were recommended to the phase II study, hoping to find a preferable method for neutropenia treatment.

show abstract

“…Therefore, we are focusing on decreasing the duration of neutropenia. Also, considering the expected median time to neutrophil recovery (> 500 cells/ µL) is 15 to 23 days, early administration of peg lgrastim may not be optimal, as it would be in most other chemotherapy regimens [8][9][10][11]. We hypothesize that delayed administration may decrease some of the early clearance of peg lgrastim by neutrophils still remaining after chemotherapy and will increase exposure later in the neutropenia course to facilitate neutrophil recovery.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of delayed pegfilgrastim administration following consolidation therapy with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) patients

Yingling,

Francis,

Seago

et al. 2024

Support Care Cancer

View full text Add to dashboard Cite

Purpose: To study the effects of delaying peg lgrastim administration following high-dose cytarabine (HiDAC) consolidation in AML patients on time to neutrophil count recovery, infectious complications, and survival. Methods: Single-center retrospective chart review of 55 patients receiving peg lgrastim as early administration (within 72 hours) or delayed administration (after 72 hours) of HiDAC.Results: The difference in neutrophil recovery time was similar between the early and delayed groups (18 days versus 19 days, P<0.28). Infections were seen in four patients in the early administration group following chemotherapy compared to none in the delayed group (p=0.04). Febrile neutropenia rates were also decreased in the delayed administration group (23.1% versus 10.3%, p=0.28) as well as longer median survival (16 months versus 19 months, p=0.69) and overall survival (21 months versus 31 months, p=0.47). Conclusion:A difference in time to neutrophil recovery was not observed between the early and delayed administration groups yet decreased infectious complications may support the delayed of administration of peg lgrastim in these patients.

show abstract

Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy

Cited by 6 publications

References 21 publications

Single dose of peg GCSF compared with daily GCSF in de novo acute myeloid leukemia patients on high dose cytarabine consolidation chemotherapy (HIDAC)

Single dose of peg GCSF compared with daily GCSF in de novo acute myeloid leukemia patients on high dose cytarabine consolidation chemotherapy (HIDAC)

A phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia

Efficacy of delayed pegfilgrastim administration following consolidation therapy with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) patients

Contact Info

Product

Resources

About